Announcements Trials
Browse Landscape

Phase

Phase 2 49Phase 1/2 14Phase NA 10Phase 3 6Phase 1 4Phase EARLY_PHASE1 3Phase 4 3Phase 2/3 3

Status

Not yet recruiting 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 2Dermatologic 2Other solid neoplasm 1Head & Neck 1Genitourinary 1

Conditions

Gastric / Gastroesophageal Junction Adenocarcinoma 2Squamous Cell Carcinoma of Head and Neck 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Oxaliplatin 21Capecitabine 19Fluorouracil 16Bevacizumab 16Esomeprazole 11Sorafenib 10Irinotecan 9Leucovorin 8Radiofrequency Ablation 7Propofol 7Bismuth 7Morphine 6Gemcitabine 6Folfox protocol 6Amoxicillin 6lenvatinib 5gadolinium ethoxybenzyl DTPA 5Tetracycline 5Sevoflurane 5S 1 (combination) 5Drug Therapy 5Control Groups 5Cisplatin 5sodium glycididazole 4fish oil triglycerides 4ferric carboxymaltose 4Sodium Chloride 4Ropivacaine 4Ribavirin 4Hepatectomy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 4 × Immune Checkpoint Inhibitors × Gastrointestinal × Clear all
NCT07405086 2026-05-22

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

OHSU Knight Cancer Institute

Phase 4 Recruiting
160 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT07149181 2025-08-29

Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regimens in Patients With Resectable Gastric Cancer/Adenocarcinoma of the Esophagogastric Junction After Radical Surgery

Liaoning Cancer Hospital & Institute

Phase 4 Not yet recruiting
1,000 enrolled
Gastrointestinal

Gastric / Gastroesophageal Junction Adenocarcinoma

NCT07132528 2025-08-20

Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as an Adjuvant Treatment After Radical Surgery for Patients With Resectable Adenocarcinoma of the Esophagogastric Junction of Gastric Cancer

Liaoning Cancer Hospital & Institute

Phase 4 Not yet recruiting
1,000 enrolled
Gastrointestinal

Gastric / Gastroesophageal Junction Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡